Tradestie Institutional Equity Comparison Engine

CELU vs ABEO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABEO Overall Edge

ABEO Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abeona Therapeutics Inc. Common Stock (ABEO) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CELU trades at N/M Forward P/E with -254.0% operating margin (-5.3% YoY revenue) versus ABEO at 18.7x Forward P/E and -186.1% operating margin (+2745.0% YoY). In options structure, CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against ABEO sits in BREAKDOWN (27th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABEO
CELU N/M vs ABEO 18.7x Fwd P/E
Growth & Margin Winner ABEO
Op Margin -254.0% vs -186.1% ยท YoY -5.3% vs +2745.0%
Momentum & Technical Winner ABEO
1Y -72.6% vs -42.4% ยท 52W Pos 2% vs 6%
Options & Structure Winner ABEO
BREAKDOWN (50th %ile IV) vs BREAKDOWN (27th %ile IV)
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
1M Return -55.9%
1Y Return -72.6%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
ABEO NASDAQ
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.42
-1.22% 1D
Market Cap $167.4M
1M Return -45.86%
1Y Return -42.38%
Forward P/E 18.7x
Unified AI Score
49.9 / 100 HOLD
Tech 60.0 Fund 61.0 Flow 67.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CELU -72.6% ABEO -42.38% Spread: +30.22 pp (ABEO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CELU Revenue ABEO Revenue CELU Op. Margin ABEO Op. Margin Margin Edge
FY2017 N/A $0M N/A -3325.7% ABEO
FY2018 N/A $0M N/A -1940.2% ABEO
FY2020 $10M $10M -1064.0% -814.2% ABEO
FY2021 $20M $0M -511.2% -2994.5% CELU
FY2022 $20M $0M -142.4% -3600.8% CELU
FY2023 $20M $0M -844.4% -1346.7% CELU
FY2024 $50M N/A -70.7% N/A CELU
FY2025 $30M $10M -230.9% -1536.9% CELU

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CELU (1) vs ABEO (9)
Institutional Metric CELU ABEO Criterion Row Winner
Market Capitalization Scale $15.2M $167.4M Larger Scale ABEO
Trailing P/E Ratio Valuation N/M 18.7x Lower Multiple ABEO
Forward P/E Ratio Valuation N/M 18.7x Lower Multiple ABEO
Revenue Growth (YoY) Growth -5.3% +2745.0% Higher Growth ABEO
Operating Margin (TTM) Profitability -254.0% -186.1% Higher Margin ABEO
Net Profit Margin Profitability -245.7% -160.3% Higher Margin ABEO
Return on Equity (ROE) Capital Efficiency -6367.2% -42.1% Higher ROE ABEO
52-Week Range Position Momentum 2% ($0โ€“$3) 6% ($2โ€“$8) Stronger Trend ABEO
Beta / 30D Volatility Risk Regime 2.01ฮฒ ยท 135% Vol 0.60ฮฒ ยท 149% Vol Lower Realized Risk CELU
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 49.9 / 100 (HOLD) Higher Composite ABEO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CELU vs ABEO Buy Guide
CELU BREAKDOWN
60d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CELU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABEO BREAKDOWN
71d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 27th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABEO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CELU nor ABEO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.